Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review

Abstract Objectives Direct-acting antivirals (DAAs) have revolutionized hepatitis C (HCV) treatment, yet their high cost necessitates rigorous economic evaluation. Glecaprevir/Pibrentasvir (GLE/PIB) and Grazoprevir/Elbasvir (GZR/EBR) are two key, highly effective DAA regimens, but their comparative...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Mojtaba Jafari, Parisa Mehdizadeh, Ehsan Teymourzadeh, Mahmood Salesi, Khosro Keshavarz, Mohammad Ali Abyazi, Mohammad Heiat, Seyed Moayed Alavian
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2025-12-01
Sarja:	Cost Effectiveness and Resource Allocation
Aiheet:	Glecaprevir/Pibrentasvir Grazoprevir/Elbasvir Hepatitis C Economic evaluation Cost-Effectiveness Systematic review
Linkit:	https://doi.org/10.1186/s12962-025-00700-1
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!